Essentials Mutations in the RASGRP2 gene represent a new inherited platelet function disorder.Report a five generation family with a novel frameshift mutation in RASGRP2 (p.F497Sfs*22).Partial platelet activation defect and serious bleeding complications in homozygous patients.Patients respond to recombinant Factor VIIa infusion but not platelet transfusions. BackgroundGenetic variants in the RASGRP2 gene encoding calcium and diacylglycerol‐regulated guanine nucleotide exchange factor I (CalDAG‐GEFI) represent a new inherited bleeding disorder linked to major defects of platelet aggregation and activation of αIIbβ3 integrin. They are of major interest as CalDAG‐GEFI is receiving attention as a potential target for antiplatelet therapy for prevention and treatment of cardiovascular disorders including arterial thrombosis and atherosclerosis.ObjectivesTo better understand the phenotypical and clinical profiles of patients with CalDAG‐GEFI deficiency.PatientsWe report a five‐generation family with a novel truncating CalDAG‐GEFI mutation detailing clinical management and phenotypic variability.ResultsPatients IV.6 & IV.4 manifested with episodes of serious mucocutanous bleeding or bleeding after surgery not responding to platelet transfusion but responding well to recombinant Factor VIIa infusions. Their blood counts and coagulation parameters were normal but platelet aggregation to ADP and collagen was defective. Further work‐up confirmed normal levels of αIIb and β3 in their platelets but decreased αIIbβ3 function. DNA analysis by whole exome sequencing within the BRIDGE‐BPD consortium (Cambridge, UK), allowed us to highlight a homozygous c.1490delT predicted to give rise to a p.F497Sfs*22 truncating mutation near to the C‐terminal domain of CalDAG‐GEFI. Sanger sequencing confirmed that both patients were homozygous for the c.1490delT and 3 out of 4 close family members were heterozygous.ConclusionsA long‐term prospective study is warranted for full clinical exploration of CalDAG‐GEFI to understand the bleeding phenotyes and their management.
The use of new generation sequencing technology has led to the recent identification of disease-causing mutations in the RASGRP2gene that encodes CalDAG-GEFI, a small GTPase-activating nucleotide exchange factor essential for integrin activation in platelets and megakaryocytes. Abrogation of CalDAG-GEFI function leads to a Glanzmann thrombasthenia (GT)-like platelet defect with a major loss in the platelet aggregation response. It is important to know the clinical profiles of patients with CalDAG-GEFI deficiency. Here we present variable phenotypes encountered in a large family with Jamaican ancestry associated with a truncating CalDAG-GEFI mutation. The initial propositus (case 1) was a 51 yr-old Jamaican man with a GT-like platelet function phenotype and absent platelet aggregation to a range of physiologic agonists (including ADP and collagen) but a normal response to ristocetin. His platelets contained a full complement of the αIIbβ3 integrin and Sanger sequencing failed to reveal any mutations in the ITGA2B and ITGB3genes. His sister presented a similar profile and flow cytometry showed that platelets of both patients bound 5-30% of the normal levels of PAC-1 after platelet stimulation with ADP thereby confirming a much decreased αIIbβ3 function. Yet western blotting confirmed normal levels of αIIb and β3 in their platelets that also contained an abundant storage pool of fibrinogen (Fg). Clot retraction occurred but was reduced and platelets bound to a Fg-covered surface (result provided by the late Professor JG White, Minneapolis, MN). DNA from case 1 was analyzed by whole exome sequencing within the BRIDGE - Bleeding and Platelet Disorders consortium (Cambridge, UK) and a homozygous c.1490delT predicted to give rise to a p.F497fs*22 truncating mutation near to the C-terminal domain of CalDAG-GEFI was highlighted in Bordeaux. Consanguinity is present within the family. Sanger sequencing performed in Marseille showed that case 1 and his sister were homozygous for the c.1490delT and that 3 (mother, aunt and niece) out of 4 close family members were heterozygous for the mutation. Transfection of human embryonic kidney (HEK) cells with the mutated CalDAG-GEFI confirmed the expression of the truncated protein. The propositus and his sister have experienced spontaneous bleeding and both have had excessive bleeding after surgery. In particular, the sister had episodes of severe epistaxis and heavy menstruation requiring frequent hospitalizations as a child with no benefit from platelet transfusions; she underwent hysterectomy and cholecystectomy under platelet transfusions and rFVIIa infusion. The propositus had episodes of gingival bleeding as a child and needed hospitalization for a tooth extraction. In 2006 he presented with headaches and was found to have a meningioma that was removed surgically (6 hours) under the cover first of platelet transfusions that again failed to prevent bleeding. This led to the use of rFVIIa that reduced bleeding despite a transient hypoxemia that led to a reduced dose and the adjunction of aminocaproic acid. The patient made a full recovery. Of interest, he has previously reported problems with wound repair namely abnormal scarring with excessive keloid. Also of note is the occurrence of ITP within 2 family members (aunt and her son who is otherwise asymptomatic) and his father died from bleeding complications following a major accident. We recommend the assembly of as much data as possible on the range of phenotypes and treatment of bleeding in families with inherited RASGRP2 defects. Disclosures No relevant conflicts of interest to declare.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.